TSH Biopharm Corp. Ltd. (8432) Stock Statistics & Valuation Metrics
Total Valuation
TSH Biopharm Corp. Ltd. has a market cap or net worth of TWD 2.25B. The enterprise value is TWD 1.19B.
- Market Cap
- TWD 2.25B
- Enterprise Value
- TWD 1.19B
Share Statistics
TSH Biopharm Corp. Ltd. has 38,398,140 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 38,398,140
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
TSH Biopharm Corp. Ltd.’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 10.02%.
- Return on Equity (ROE)
- 0.10
- Return on Assets (ROA)
- 0.07
- Return on Invested Capital (ROIC)
- 10.02%
- Return on Capital Employed (ROCE)
- 0.13
- Revenue Per Employee
- 16.71M
- Profits Per Employee
- 1.74M
- Employee Count
- 80
- Asset Turnover
- 0.68
- Inventory Turnover
- 4.36
Valuation Ratios
The current PE Ratio of TSH Biopharm Corp. Ltd. is 11.36. TSH Biopharm Corp. Ltd.’s PEG ratio is 0.17.
- PE Ratio
- 11.36
- PS Ratio
- 1.55
- PB Ratio
- 2.41
- Price to FCF
- 8.05
- Price to Operating Cash Flow
- 11.48
- PEG Ratio
- 0.17
Income Statement
In the last 12 months, TSH Biopharm Corp. Ltd. had revenue of 1.34B and earned 139.26M in profits. Earnings per share was 3.63.
- Revenue
- 1.34B
- Gross Profit
- 657.13M
- Operating Income
- 218.37M
- Pretax Income
- 234.79M
- Net Income
- 139.26M
- EBITDA
- 245.11M
- Earnings Per Share (EPS)
- 3.63
Cash Flow
In the last 12 months, operating cash flow was 297.28M and capital expenditures -1.48M, giving a free cash flow of 295.80M billion.
- Operating Cash Flow
- 297.28M
- Free Cash Flow
- 295.80M
- Free Cash Flow per Share
- 5.37
Dividends & Yields
TSH Biopharm Corp. Ltd. pays an annual dividend of ―, resulting in a dividend yield of 4.45%
- Dividend Per Share
- ―
- Dividend Yield
- 4.45%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 12.55%
- Earnings Yield
- 7.97%
Stock Price Statistics
- Beta
- 0.20
- 52-Week Price Change
- 6.34%
- 50-Day Moving Average
- 52.84
- 200-Day Moving Average
- 50.70
- Relative Strength Index (RSI)
- 64.85
- Average Volume (3m)
- 72.26K
Important Dates
TSH Biopharm Corp. Ltd. upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
TSH Biopharm Corp. Ltd. as a current ratio of 6.27, with Debt / Equity ratio of 1.83%
- Current Ratio
- 6.27
- Quick Ratio
- 5.58
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -1.79
- Interest Coverage Ratio
- 273.99
Taxes
In the past 12 months, TSH Biopharm Corp. Ltd. has paid 46.97M in taxes.
- Income Tax
- 46.97M
- Effective Tax Rate
- 0.20
Enterprise Valuation
TSH Biopharm Corp. Ltd. EV to EBITDA ratio is 5.28, with an EV/FCF ratio of 5.93.
- EV to Sales
- 1.15
- EV to EBITDA
- 5.28
- EV to Free Cash Flow
- 5.93
- EV to Operating Cash Flow
- 5.90
Balance Sheet
TSH Biopharm Corp. Ltd. has TWD 1.07B in cash and marketable securities with TWD 15.80M in debt, giving a net cash position of TWD 1.06B billion.
- Cash & Marketable Securities
- TWD 1.07B
- Total Debt
- TWD 15.80M
- Net Cash
- TWD 1.06B
- Net Cash Per Share
- TWD 27.50
- Tangible Book Value Per Share
- TWD 36.13
Margins
Gross margin is 51.91%, with operating margin of 20.79%, and net profit margin of 17.59%.
- Gross Margin
- 51.91%
- Operating Margin
- 20.79%
- Pretax Margin
- 22.02%
- Net Profit Margin
- 17.59%
- EBITDA Margin
- 21.69%
- EBIT Margin
- 20.79%
Analyst Forecast
The average price target for TSH Biopharm Corp. Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 20.56%
- EPS Growth Forecast
- 67.73%
